Röver et al. (2018) demonstrated that PDCD1 promoter methylation is a prognostic factor in patients with lower-grade gliomas harboring IDH mutations, suggesting that epigenetic silencing of PDCD1 could modulate immune evasion in the tumor microenvironment [33]. This evidence concerns the gene PDCD1 and glioma.